June 21 (Reuters) - Eli Lilly ( LLY ) said on Saturday

its experimental pill orforglipron helped diabetics lose weight

and lower their blood sugar, and the company aims to announce in

the third quarter trial results for the drug in overweight and

obese people without diabetes.

Lilly expects to submit the non-diabetes Phase 3 data to

global regulatory agencies by the end of the year, said Ken

Custer, head of cardiometabolic health at the company. The U.S.

Food and Drug Administration typically makes new drug approval

decisions 10 months after a manufacturer's submission.

Lilly said it plans to file for regulatory approvals for

orforglipron as a diabetes treatment in 2026.

Full results of the diabetes trial were presented at the

annual meeting of the American Diabetes Association in Chicago.

The Phase 3 study showed that type 2 diabetes patients

taking the highest dose of daily orforglipron lost nearly 8% of

their body weight over 40 weeks. That compares favorably with

Novo Nordisk's injected drug Ozempic, for which

trials showed that diabetic patients on the highest dose lost

roughly 6% of their body weight.

Lilly's pill, which can be taken without food or water,

lowered blood sugar levels by an average of 1.3% to 1.6% across

doses.

The company said the most frequently reported side effects

were gastrointestinal and similar to other GLP-1 drugs,

including diarrhea and vomiting.

Custer said Lilly's goal in its non-diabetes trials is to

achieve weight loss consistent with GLP-1 drugs that are

currently available. Ozempic was shown in trials to lead to

weight loss of 15% for people without diabetes over 68 weeks.

He said orforglipron, which has a simpler production process

than injected GLP-1 drugs such as Ozempic or Lilly's Zepbound

and does not require cold storage, could mean wider global

access to weight-loss drugs.

"This is the type of molecule that is going to allow us to

reach the broader globe," Custer said.

The executive declined to comment on pricing plans for

orforglipron.